S&P 500

5.631,22

0,28%

Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.

Registrieren

SANA

Sana Biotechnology (SANA)

Sana Biotechnology Inc

Von:

Regulatory News

Text Search:

Sortieren nach:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:SANA

<< Previous 1 2 3 4 5 6 7 Next >>

Datum	Zeit	Quelle	Überschrift	Symbol	Firma
11/12/2023	15h00	GlobeNewswire Inc.	Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting	NASDAQ:SANA	Sana Biotechnology Inc
01/12/2023	22h05	GlobeNewswire Inc.	Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System	NASDAQ:SANA	Sana Biotechnology Inc
28/11/2023	01h01	PR Newswire (US)	Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders	NASDAQ:SANA	Sana Biotechnology Inc
21/11/2023	15h00	GlobeNewswire Inc.	Sana Biotechnology to Present at November and December 2023 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
21/11/2023	12h00	PR Newswire (US)	Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics	NASDAQ:SANA	Sana Biotechnology Inc
17/11/2023	15h00	GlobeNewswire Inc.	Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes	NASDAQ:SANA	Sana Biotechnology Inc
09/11/2023	22h05	GlobeNewswire Inc.	Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis	NASDAQ:SANA	Sana Biotechnology Inc
08/11/2023	22h24	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SANA	Sana Biotechnology Inc
08/11/2023	22h14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
08/11/2023	22h05	GlobeNewswire Inc.	Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
03/11/2023	21h08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
03/11/2023	21h07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:SANA	Sana Biotechnology Inc
02/11/2023	14h05	GlobeNewswire Inc.	Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting	NASDAQ:SANA	Sana Biotechnology Inc
01/11/2023	15h30	PR Newswire (US)	Flagship Pioneering Launches Pioneering Intelligence	NASDAQ:SANA	Sana Biotechnology Inc
10/10/2023	22h21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
10/10/2023	22h15	GlobeNewswire Inc.	Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M	NASDAQ:SANA	Sana Biotechnology Inc
13/09/2023	12h04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
11/09/2023	12h30	PR Newswire (US)	Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer	NASDAQ:SANA	Sana Biotechnology Inc
30/08/2023	22h05	GlobeNewswire Inc.	Sana Biotechnology to Present at September 2023 Investor Conferences	NASDAQ:SANA	Sana Biotechnology Inc
29/08/2023	15h00	PR Newswire (US)	Invaio achieves first registration for citrus greening solution featuring Trecise™ technology	NASDAQ:SANA	Sana Biotechnology Inc
21/08/2023	22h05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
03/08/2023	22h23	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:SANA	Sana Biotechnology Inc
03/08/2023	22h14	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:SANA	Sana Biotechnology Inc
03/08/2023	22h05	GlobeNewswire Inc.	Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates	NASDAQ:SANA	Sana Biotechnology Inc
16/06/2023	15h00	GlobeNewswire Inc.	Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting	NASDAQ:SANA	Sana Biotechnology Inc
09/06/2023	22h35	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SANA	Sana Biotechnology Inc
09/06/2023	22h35	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SANA	Sana Biotechnology Inc
09/06/2023	22h35	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SANA	Sana Biotechnology Inc
09/06/2023	22h34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SANA	Sana Biotechnology Inc
09/06/2023	22h34	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NASDAQ:SANA	Sana Biotechnology Inc